Baxalta collaborates with Precision BioSciences on CAR T cell therapies

26 February 2016

USA biotech firm Baxalta (NYSE: BXLT) has entered into a collaboration with genome editing company Precision BioSciences to develop a series of allogeneic chimeric antigen receptor (CAR) T cell therapies for a range of cancers, it has been announced.

CAR T is widely recognized as a breakthrough technology with the potential to become a curative option for certain malignancies.

David Meek, executive vice president of Baxalta, said: “Collaborating with Precision BioSciences enables Baxalta to accelerate innovation in immune-oncology with a next-generation, donor-derived CAR T strategy using a proprietary combination of genome editing expertise and technology enables the production of CAR T cells derived from healthy donors rather than relying on the patient.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK